PD
KROS icon

Point72 (DIFC)’s Keros Therapeutics KROS Stock Holding History

Point72 (DIFC)’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$15.3K Buy
+964
New +$14.2K ﹤0.01% 895
2025
Q1 		– Sell
-9,078
Closed -$144K – 1884
2024
Q4 		$144K Sell
9,078
-10,177
-53% -$529K 0.01% 936
2024
Q3 		$1.12M Buy
19,255
+1,715
+10% +$84.7K 0.04% 460
2024
Q2 		$802K Buy
+17,540
New +$943K 0.03% 562

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Point72 (DIFC)'s KROS Position: Q3 2025 in Review

Point72 (DIFC) opened a new position in Keros Therapeutics (KROS) in Q3 2025: 964 shares worth $15.3K. The stake represents ﹤0.01% of the portfolio and ranks #895 among its holdings. This is a return to the name: Point72 (DIFC) previously reported a position in KROS as recently as Q4 2024.

Point72 (DIFC) first reported a position in KROS in Q2 2024 and has held it in 4 quarters since. The position peaked at $1.12M in Q3 2024. 155 funds tracked by Wall St. Rank hold KROS as of Q3 2025.

  • Point72 (DIFC) held 964 shares of Keros Therapeutics worth $15.3K as of Q3 2025.
  • Keros Therapeutics was a new Point72 (DIFC) position in Q3 2025.
  • Keros Therapeutics made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #895 holding.
  • Point72 (DIFC) first reported a position in Keros Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • Point72 (DIFC)'s Keros Therapeutics position peaked at $1.12M in Q3 2024.
  • 155 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.